Merck & Co., Inc. is a global healthcare leader with operations spanning two core divisions: Pharmaceuticals and Animal Health. The Pharmaceutical segment is dedicated to human health, offering a broad spectrum of medicinal products. These cover crucial therapeutic areas such as oncology, acute hospital care, immunolog…
An institutional-grade, numbers-driven thesis on MRK — generated on demand from live fundamentals, scores and forecast.
Member feature · 7-day free trial · no charge today · cancel anytime
As of August 7, 2026, TradersQuant's model rates Merck & Co., Inc. (MRK) 62/100 with a 12-month base-case forecast of $140.64 — +9.6% versus the current price of $128.35. Merck & Co., Inc. trades at $128.35 in the Healthcare sector, with a market capitalisation of $317.00B. The score blends valuation, growth, earnings quality and momentum into a single grade.
The 12-month analyst consensus price target for MRK is $140.64, implying +9.6% versus the current price. The model's 12-month scenario range runs from $193.21 (bear) to $217.25 (bull), with a base case of $200.47.
On the fundamentals, Merck & Co. shows a P/E of 36.1, trailing revenue of $64.93B, revenue growth of +1.2% YoY, a dividend yield of 2.62%. This page also tracks MRK's short interest, institutional (smart-money) positioning and the options market — the same cross-signal view institutions watch.
MRK currently carries a TradersQuant composite score of 62/100, which we read as a neutral-to-watch signal. The Wall-Street analyst consensus is "Buy". Our 12-month price target of $140.64 implies +9.6% from $128.35. This is research, not financial advice — always combine it with your own judgement.
The analyst consensus price target for MRK is $140.64, about +9.6% versus the latest price of $128.35. Consensus is based on 37 analysts.
TradersQuant's 12-month model forecast for MRK is a base case of $200.47, ranging from $193.21 (bear) to $217.25 (bull), an expected return of +56.2%. Forecasts are model estimates, not guarantees.
The TradersQuant price prediction for MRK over the next 12 months is $200.47 in the base case (bear $193.21, bull $217.25), versus today's price of $128.35. Unlike black-box prediction sites, every TradersQuant call is logged at the price and date it was made and graded publicly against the S&P 500.
We deliberately don't publish 2030 price predictions for MRK — no model can honestly forecast a single stock five-plus years out, and sites that do are guessing. TradersQuant focuses on a rigorous 12-month bull/base/bear range, refreshed continuously and graded on our public track record.
TradersQuant estimates MRK's fair value at $140.64, implying +9.6% of expected upside versus the current price.
Yes — Merck & Co. pays a dividend yielding 2.62% (about $3.36 per share annually).
Data and model outputs are for research only and are not financial advice. Figures update continuously.
